What is Causaly?
Founded in 2018, Causaly has established itself as a transformative force in the life sciences sector by leveraging advanced artificial intelligence to navigate the complexities of biomedical data. The company's platform serves as a sophisticated catalyst for research organizations, enabling them to synthesize vast amounts of information into actionable insights. By automating the discovery process, Causaly addresses the critical bottlenecks in drug development, effectively redefining how researchers identify, analyze, and apply scientific knowledge to solve complex biological challenges. Its market position is bolstered by a robust technological architecture that integrates seamlessly into the workflows of global research institutions.
How much funding has Causaly raised?
Causaly has raised a total of $81.8M across 3 funding rounds:
Series A
$4.8M
Unspecified
$17M
Series B
$60M
Series A (2019): $4.8M with participation from Ebrd Vcip, Marathon Venture Capital, and Pentech Ventures
Unspecified (2021): $17M led by EBRD, Index Ventures, Pentech, and Marathon
Series B (2023): $60M supported by ICONIQ Growth, Marathon Venture Capital, Index Ventures, and Pentech
Key Investors in Causaly
ICONIQ Growth
A prominent growth equity firm that partners with visionary entrepreneurs to scale category-defining companies from early growth stages to IPO.
Index Ventures
A global venture capital firm known for backing transformative technology companies from seed through to public offering.
Marathon Venture Capital
A specialized seed-stage fund focused on supporting ambitious European founders in building world-class technology companies within the AI and biopharma sectors.
What's next for Causaly?
With the infusion of this recent capital, Causaly is poised to scale its operations and deepen its technological moat. The strategic focus will likely center on expanding its AI capabilities to cover broader therapeutic areas and enhancing its predictive modeling features. As the company matures, it is expected to prioritize international market penetration and the formation of high-value partnerships with major pharmaceutical entities. By maintaining its trajectory of innovation, Causaly is well-positioned to become the industry standard for data-driven decision-making in the life sciences, ultimately shortening the time-to-market for life-saving therapies.
See full Causaly company page
